Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark-Friedrich Hurdle

Pain Medicine Jacksonville, FL Medical Doctor

NPI 1952374043 CMS profile 1130892

4500 San Pablo Rd S, Jacksonville, FL 32224

Open in the dashboard

General payments

$139,860

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark-Friedrich Hurdle of Jacksonville, FL is reported in the CMS Open Payments database as having received $139,860 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $414 5
2024 General $1,558 12
2023 General $37,443 39
2022 General $25,029 24
2021 General $26,567 17
2020 General $8,448 10
2019 General $40,400 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark-Friedrich Hurdle
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Mark-Friedrich Hurdle were reported at $414. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Mark-Friedrich Hurdle Pain Medicine median Middle half National median
2019 $40,400 $506 $144–$1,566 $163
2020 $8,448 $315 $96–$934 $114
2021 $26,567 $452 $134–$1,237 $132
2022 $25,029 $475 $124–$1,407 $149
2023 $37,443 $480 $136–$1,384 $160
2024 $1,558 $521 $164–$1,511 $164
2025 $414 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Avanos Medical $98,380 54 payments
  2. SPR Therapeutics, Inc $31,110 44 payments
  3. Bioventus LLC $9,548 14 payments
  4. Bioness Inc $310 1 payment
  5. Stratus Medical, LLC $174 2 payments
  6. MML US, Inc. $150 1 payment
  7. Abbott Laboratories $145 2 payments
  8. Pacira Pharmaceuticals Incorporated $42 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $104,851 26 payments
  2. Travel and Lodging $17,061 40 payments
  3. Honoraria $7,115 2 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,475 3 payments
  5. Food and Beverage $4,049 47 payments
  6. Entertainment $310 1 payment
Products named General payments · program years 2019–2025
  1. GENERATOR $49,401 38 payments
  2. COOLIEF* COOLED RADIOFREQUENCY $40,370 13 payments
  3. SPRINT PNS System $31,110 44 payments
  4. COOLIEF $8,610 3 payments
  5. Stimrouter Implantable Kit $7,973 13 payments
  6. Stimrouter for Pain $310 1 payment
  7. Nimbus $174 2 payments
  8. ReActiv8 $150 1 payment
  9. ETERNA $145 2 payments
  10. Iovera $42 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

201

Median for Pain Management: 951

Drug cost

$14,132

Median for Pain Management: $26,034

Branded share of claims

34.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 14 $10,529
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 29 $1,205
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $908
Oxycodone Hcl Generic 59 $769
Pregabalin Generic 17 $285
Gabapentin Generic 21 $192
Hydromorphone Hcl Generic 18 $155
Tramadol Hcl Generic 16 $89

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$85,661

Medicare's payments for the services billed

Medicare patients

555

Average age 75

Services billed

1,290

317 women, 238 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Depression 31%
Chronic kidney disease 29%
Diabetes 25%
Atrial fibrillation 23%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record